[{"id":"421063e1-092c-4069-8aae-f069c4e61471","acronym":"","url":"https://clinicaltrials.gov/study/NCT01174108","created_at":"2021-01-18T04:41:02.291Z","updated_at":"2025-02-25T15:25:06.019Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells","source_id_and_acronym":"NCT01174108","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" TERT • GATA2","pipe":" | ","alterations":" TERT mutation • GATA2 mutation","tags":["TERT • GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • GATA2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/10/2010","start_date":" 12/10/2010","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-11"},{"id":"eb5c9ee3-620e-48d0-bab8-f8f2914ede1d","acronym":"NRG-BN010","url":"https://clinicaltrials.gov/study/NCT04729959","created_at":"2021-03-09T19:55:01.650Z","updated_at":"2024-07-02T16:34:27.180Z","phase":"Phase 2","brief_title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","source_id_and_acronym":"NCT04729959 - NRG-BN010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Actemra IV (tocilizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-11"},{"id":"8fd31dd0-c717-4033-9f44-afbf209f365e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04225039","created_at":"2021-03-09T19:53:36.498Z","updated_at":"2024-07-02T16:35:12.728Z","phase":"Phase 2","brief_title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","source_id_and_acronym":"NCT04225039","lead_sponsor":"University of Pennsylvania","biomarkers":" MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • ragifilimab (INCAGN1876)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 09/08/2022","primary_completion_date":" 09/08/2022","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-26"},{"id":"50f8b205-06c7-4e3e-b459-1ebbfce2f273","acronym":"","url":"https://clinicaltrials.gov/study/NCT04910022","created_at":"2021-06-02T20:57:18.421Z","updated_at":"2024-07-02T16:35:14.620Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT04910022","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" EGFR • IDH1 • IDH2 • MGMT • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • IDH1 • IDH2 • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • itareparib (NMS-293)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-15"},{"id":"aebfc79a-06bb-47ab-a81d-a5954af2fab2","acronym":"PATHWAyS","url":"https://clinicaltrials.gov/study/NCT05900908","created_at":"2023-06-13T17:07:56.192Z","updated_at":"2024-07-02T16:35:19.451Z","phase":"Phase 4","brief_title":"Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy","source_id_and_acronym":"NCT05900908 - PATHWAyS","lead_sponsor":"GT Medical Technologies, Inc.","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-02-14"},{"id":"9ac5a259-2a1d-4705-a42a-0a8634a71850","acronym":"","url":"https://clinicaltrials.gov/study/NCT06236464","created_at":"2024-02-01T18:21:37.212Z","updated_at":"2024-07-02T16:35:21.338Z","phase":"","brief_title":"Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas","source_id_and_acronym":"NCT06236464","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" TERT","pipe":" | ","alterations":" TERT mutation • TERT promoter mutation","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • TERT promoter mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 11/19/2025","primary_completion_date":" 11/19/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-02-01"},{"id":"1e7d842e-e4ca-4d95-b896-1da6f52d2d98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03726515","created_at":"2021-01-18T18:15:36.195Z","updated_at":"2024-07-02T16:35:44.942Z","phase":"Phase 1","brief_title":"CART-EGFRvIII + Pembrolizumab in GBM","source_id_and_acronym":"NCT03726515","lead_sponsor":"University of Pennsylvania","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • LXF821"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 02/27/2021","primary_completion_date":" 02/27/2021","study_txt":" Completion: 02/27/2021","study_completion_date":" 02/27/2021","last_update_posted":"2023-06-22"},{"id":"6f24da17-d18e-4f79-befe-3764e25c2b19","acronym":"","url":"https://clinicaltrials.gov/study/NCT05271240","created_at":"2022-03-08T16:52:43.604Z","updated_at":"2024-07-02T16:35:47.014Z","phase":"Phase 3","brief_title":"Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM","source_id_and_acronym":"NCT05271240","lead_sponsor":"Northwell Health","biomarkers":" EGFR • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 432","initiation":"Initiation: 04/27/2022","start_date":" 04/27/2022","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-05-29"},{"id":"9281feb2-76be-43ef-aaa8-b34124c78001","acronym":"","url":"https://clinicaltrials.gov/study/NCT04924127","created_at":"2021-06-11T18:56:22.686Z","updated_at":"2024-07-02T16:35:50.094Z","phase":"","brief_title":"Molecular Pathology Research Project of Glioma","source_id_and_acronym":"NCT04924127","lead_sponsor":"Jinsong Wu","biomarkers":" TERT","pipe":" | ","alterations":" TERT mutation • TERT promoter mutation","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • TERT promoter mutation"],"overall_status":"Completed","enrollment":" Enrollment 976","initiation":"Initiation: 12/05/2019","start_date":" 12/05/2019","primary_txt":" Primary completion: 06/06/2021","primary_completion_date":" 06/06/2021","study_txt":" Completion: 12/20/2021","study_completion_date":" 12/20/2021","last_update_posted":"2023-04-19"},{"id":"aab294a4-1ca3-4b85-ab41-94be4ce929be","acronym":"","url":"https://clinicaltrials.gov/study/NCT04904419","created_at":"2021-05-27T12:53:02.570Z","updated_at":"2024-07-02T16:35:50.199Z","phase":"","brief_title":"Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection","source_id_and_acronym":"NCT04904419","lead_sponsor":"Jinsong Wu","biomarkers":" BRAF • TERT","pipe":" | ","alterations":" BRAF V600E • TERT mutation","tags":["BRAF • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • TERT mutation"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 01/31/2022","primary_completion_date":" 01/31/2022","study_txt":" Completion: 01/31/2022","study_completion_date":" 01/31/2022","last_update_posted":"2023-04-18"},{"id":"93bff278-c608-420e-b03d-f427d89bfe6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00604201","created_at":"2021-01-18T02:14:32.083Z","updated_at":"2024-07-02T16:36:18.819Z","phase":"Phase 2","brief_title":"Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome","source_id_and_acronym":"NCT00604201","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" TERT • CD34 • HLA-B • HLA-C","pipe":" | ","alterations":" TERT mutation","tags":["TERT • CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 05/21/2008","start_date":" 05/21/2008","primary_txt":" Primary completion: 10/25/2016","primary_completion_date":" 10/25/2016","study_txt":" Completion: 09/14/2021","study_completion_date":" 09/14/2021","last_update_posted":"2022-01-05"},{"id":"cc53a890-89ed-4959-a512-acb62dcd9222","acronym":"HELP-2020","url":"https://clinicaltrials.gov/study/NCT04506398","created_at":"2021-06-24T18:52:50.426Z","updated_at":"2024-07-02T16:36:28.684Z","phase":"","brief_title":"Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence","source_id_and_acronym":"NCT04506398 - HELP-2020","lead_sponsor":"RenJi Hospital","biomarkers":" TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3","pipe":" | ","alterations":" CTNNB1 mutation • TERT mutation • TERT promoter mutation","tags":["TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation • TERT mutation • TERT promoter mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/10/2020","start_date":" 09/10/2020","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2021-06-24"},{"id":"be90799f-136d-496d-adb9-c7981cf760f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04792437","created_at":"2021-03-11T13:52:40.593Z","updated_at":"2024-07-02T16:36:32.874Z","phase":"","brief_title":"Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data","source_id_and_acronym":"NCT04792437","lead_sponsor":"Yu Yao, MD","biomarkers":" PD-L1 • TMB • CD8 • TERT • PD-1 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD8 expression • TERT mutation","tags":["PD-L1 • TMB • CD8 • TERT • PD-1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD8 expression • TERT mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2021-03-24"},{"id":"364d749a-b5ae-4945-89a9-9b51257b45c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01567202","created_at":"2021-01-18T06:38:44.773Z","updated_at":"2024-07-02T16:36:41.251Z","phase":"Phase 2","brief_title":"Study of DC Vaccination Against Glioblastoma","source_id_and_acronym":"NCT01567202","lead_sponsor":"Huashan Hospital","biomarkers":" IDH1 • IDH2 • TERT","pipe":" | ","alterations":" RAS wild-type • TERT mutation • IDH wild-type","tags":["IDH1 • IDH2 • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • TERT mutation • IDH wild-type"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2020-09-09"},{"id":"f1721518-a42e-44fe-b635-b90fb571dc99","acronym":"MOLTHYSO","url":"https://clinicaltrials.gov/study/NCT04053114","created_at":"2021-01-18T19:52:23.740Z","updated_at":"2024-07-02T16:36:57.060Z","phase":"","brief_title":"MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii","source_id_and_acronym":"NCT04053114 - MOLTHYSO","lead_sponsor":"Institut Bergonié","biomarkers":" ALK • HRAS • AKT1 • TERT • CTNNB1","pipe":" | ","alterations":" ALK translocation • TERT mutation • FGFR3 expression • CTNNB1 expression","tags":["ALK • HRAS • AKT1 • TERT • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • TERT mutation • FGFR3 expression • CTNNB1 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2019-08-12"},{"id":"4089d77e-fd91-4665-b6b6-7746742e0a38","acronym":"","url":"https://clinicaltrials.gov/study/NCT03750890","created_at":"2021-01-18T18:23:27.032Z","updated_at":"2024-07-02T16:37:01.335Z","phase":"","brief_title":"Visual Study of Molecular Genotype in Glioma Evolution","source_id_and_acronym":"NCT03750890","lead_sponsor":"Tongji Hospital","biomarkers":" EGFR • TP53 • PTEN • MGMT • TERT • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • PTEN mutation • ATRX mutation • TERT mutation • EGFR mutation + PTEN mutation","tags":["EGFR • TP53 • PTEN • MGMT • TERT • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • PTEN mutation • ATRX mutation • TERT mutation • EGFR mutation + PTEN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2019-03-26"},{"id":"2fbf63a3-c5d3-4871-867d-819c244d5d8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02685592","created_at":"2021-01-18T13:05:56.005Z","updated_at":"2024-07-02T16:37:10.399Z","phase":"Phase 4","brief_title":"Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream","source_id_and_acronym":"NCT02685592","lead_sponsor":"Joint Authority for Päijät-Häme Social and Health Care","biomarkers":" TERT • MITF","pipe":" | ","alterations":" TERT mutation","tags":["TERT • MITF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameluz (aminolevulinic acid)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 03/01/2018","study_completion_date":" 03/01/2018","last_update_posted":"2018-05-30"},{"id":"09b798c5-a6f6-44d0-968a-d13396500709","acronym":"","url":"https://clinicaltrials.gov/study/NCT02766270","created_at":"2021-01-18T13:33:56.349Z","updated_at":"2024-07-02T16:37:26.356Z","phase":"Phase 1","brief_title":"CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas","source_id_and_acronym":"NCT02766270","lead_sponsor":"Beijing Tiantan Hospital","biomarkers":" TERT","pipe":" | ","alterations":" TERT mutation • IDH wild-type • TERT promoter mutation","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 09/26/2016","start_date":" 09/26/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-01-20"}]